Puma Biotechnology (PBYI) Non-Current Debt (2011 - 2025)

Puma Biotechnology has reported Non-Current Debt for 8 years, with the latest figure at $10.9 million in Q2 2025.

• For the quarter ending Q2 2025, Non-Current Debt fell 75.15% year-over-year to $10.9 million; the trailing twelve-month figure through Jun 2025 stood at $10.9 million (down 75.15% YoY), and the FY2024 full-year result was $21.7 million, down 66.92% from the prior year.
• Non-Current Debt for Q2 2025 stood at $10.9 million, up from $10.6 million in the prior quarter.
• The five-year high for Non-Current Debt was $98.6 million in Q1 2023, with the low at $10.6 million in Q1 2025.
• Historically, Non-Current Debt has averaged $68.5 million across 5 years, with a median of $76.5 million in 2021.
• Annual changes were most pronounced in 2022 — Non-Current Debt jumped 42.17% — and 2025, when it tumbled 80.53%.
• Puma Biotechnology's Non-Current Debt stood at $97.1 million in 2021, then rose by 1.25% to $98.3 million in 2022, then tumbled by 33.21% to $65.7 million in 2023, then slumped by 66.92% to $21.7 million in 2024, then plunged by 49.96% to $10.9 million in 2025.
• The last three Non-Current Debt figures came in at $10.9 million (Q2 2025), $10.6 million (Q1 2025), and $21.7 million (Q4 2024), per Business Quant data.